Drug Profile
Research programme: protozoal infection therapeutics - aRigen
Alternative Names: ARA-01; ARA-02; ARA-03; ARA-04Latest Information Update: 28 Nov 2018
Price :
$50
*
At a glance
- Originator aRigen
- Class Antiprotozoals; Leishmaniasis vaccines; Sesquiterpenes; Small molecules
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported African trypanosomiasis; Amoebiasis; Cryptosporidiosis; Leishmaniasis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in African trypanosomiasis in Japan
- 24 Feb 2010 Preclinical development is ongoing in Japan
- 07 Dec 2006 Preclinical trials in African trypanosomiasis in Japan (unspecified route)